Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 15/20 | 0.52 |
| ▸ | DRD3 | P35462 | 15/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23929169 | 0.85 | DRD2 (0.48) | DRD2DRD3 | |
| SCHEMBL3654090 | 0.82 | DRD2 (0.52) | DRD2DRD3 | |
| SCHEMBL7799385 | 0.82 | ITGB3 (0.58) | ITGB3ITGA2BDRD2DRD3CD274 | |
| SCHEMBL3843083 | 0.81 | ESR2 (0.57) | DRD2DRD3ESR1ESR2 | |
| SCHEMBL1602268 | 0.80 | DRD2 (0.51) | DRD2DRD3 | |
| SCHEMBL13094748 | 0.78 | DRD1 (0.56) | DRD2DRD3ESR1ESR2 | |
| SCHEMBL8179719 | 0.76 | ESR1 (0.45) | DRD2DRD3ESR1ESR2 | |
| SCHEMBL7799399 | 0.76 | ITGB3 (0.64) | ITGB3ITGA2B | |
| SCHEMBL13144731 | 0.76 | DRD2 (0.51) | DRD2DRD3 | |
| SCHEMBL7798156 | 0.76 | ITGB3 (0.54) | ITGB3ITGA2BDRD2DRD3CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | ITGB3 132/4885ITGA2B 106/4885DRD2 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.